OGG1 and ovarian carcinoma: These data imply that an identified DNA glycosylase dysfunction or a concurrent hOGG1-targeted therapy may possibly help in clinical trials involving patients with BRCA1/2-mutated or not ovarian carcinoma treated with PARP inhibitors[36-39].